Background: Data regarding admission HbA1c and long-term outcome in non-diabetic patients undergoing percutaneous coronary intervention for acute myocardial infarction are limited. This study examined the value of admission HbA1c in clinical outcomes after percutaneous coronary intervention in non-diabetic patients with acute myocardial infarction. Methods: We analyzed data from 318 eligible patients undergoing a 1-year follow-up after PCI for acute myocardial infarction from Oct 2005 and Jan 2008. The patients were divided on the basis of admission HbA1c level: group 1, <7 %; and group 2, > or = 7 %. Results: The mean HbA1c level of total patients was 6.18 짹 0.79 %. There were no significant differences in age, sex, comorbidities, blood pressure, Killip class, creatinine clearance, left ventricular ejection fraction, high-sensitivity C-reactive protein (hsCRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and angiographic findings between two groups. Our data showed no significant differences in 1-month major cardiac events (15 deaths, 3 MI, 4 repeat PCI and 0 CABG) and 12-month mortality between two groups. Conclusion: Admission HbA1c is not a predictor of adverse clinical outcome in non-diabetic patients undergoing percutaneous coronary intervention for acute myocardial infarction.